(Q54106027)

24 May 2018

title

A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. (English)

1 reference

24 May 2018

1 reference

C H van Nispen

1

1 reference

24 May 2018

A I Hoepelman

2

1 reference

24 May 2018

M Rozenberg-Arska

3

1 reference

24 May 2018

J Verhoef

4

1 reference

24 May 2018

L Purkins

5

1 reference

24 May 2018

S A Willavize

6

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 December 1998

1 reference

24 May 2018

The American Journal of Surgery

published in

1 reference

24 May 2018

volume

176

1 reference

24 May 2018

issue

6A Suppl

1 reference

24 May 2018

page(s)

27S-31S

1 reference

24 May 2018

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Impact of oral ciprofloxacin on the faecal flora of healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

In vitro activity of the new fluoroquinolone CP-99,219.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

The chemistry and biological profile of trovafloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900217-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9610(98)00217-7

1 reference

24 May 2018

1 reference

24 May 2018